John Paul Clancy
Overview
Explore the profile of John Paul Clancy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mayer-Hamblett N, Clancy J, Jain R, Donaldson S, Fajac I, Goss C, et al.
Lancet Respir Med
. 2023 Sep;
11(10):932-944.
PMID: 37699421
The growing use of modulator therapies aimed at restoring cystic fibrosis transmembrane conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally altered clinical trial strategies needed to...
2.
Hisert K, Birket S, Clancy J, Downey D, Engelhardt J, Fajac I, et al.
Lancet Respir Med
. 2023 Sep;
11(10):916-931.
PMID: 37699420
Cystic fibrosis is a multiorgan disease caused by impaired function of the cystic fibrosis transmembrane conductance regulator (CFTR). Since the introduction of the CFTR modulator combination elexacaftor-tezacaftor-ivacaftor (ETI), which acts...
3.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson S, Riekert K, Sawicki G, et al.
Lancet Respir Med
. 2022 Nov;
11(4):329-340.
PMID: 36343646
Background: Reducing treatment burden is a priority for people with cystic fibrosis, whose health has benefited from using new modulators that substantially increase CFTR protein function. The SIMPLIFY study aimed...
4.
Bilton D, Fajac I, Pressler T, Clancy J, Sands D, Minic P, et al.
J Cyst Fibros
. 2021 Jun;
20(6):1010-1017.
PMID: 34144923
Background: . In CLEAR-108-a phase 3, randomised, open-label study-once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic...
5.
Pearson K, Mayer-Hamblett N, Goss C, Retsch-Bogart G, Vandalfsen J, Burks P, et al.
J Cyst Fibros
. 2020 Dec;
20(2):195-197.
PMID: 33349583
The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted CF clinical research within the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN). A Research Electronic Data Capture (REDCap)...
6.
Wolfe C, Pestian T, Gecili E, Su W, Keogh R, Pestian J, et al.
JMIR Med Inform
. 2020 Dec;
8(12):e23530.
PMID: 33325834
Background: Despite steady gains in life expectancy, individuals with cystic fibrosis (CF) lung disease still experience rapid pulmonary decline throughout their clinical course, which can ultimately end in respiratory failure....
7.
Hudock K, Collins M, Imbrogno M, Snowball J, Kramer E, Brewington J, et al.
Am J Physiol Lung Cell Mol Physiol
. 2020 Mar;
319(1):L137-L147.
PMID: 32159969
Neutrophil extracellular traps (NETs) provide host defense but can contribute to the pathobiology of diverse human diseases. We sought to determine the extent and mechanism by which NETs contribute to...
8.
Bilton D, Pressler T, Fajac I, Clancy J, Sands D, Minic P, et al.
J Cyst Fibros
. 2019 Aug;
19(2):284-291.
PMID: 31451351
Background: Shortcomings of inhaled antibiotic treatments for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) include poor drug penetration, inactivation by sputum, poor efficiency due to protective biofilm, and...
9.
Clancy J, Cotton C, Donaldson S, Solomon G, VanDevanter D, Boyle M, et al.
J Cyst Fibros
. 2018 Jun;
18(1):22-34.
PMID: 29934203
Background: New drugs that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein with discreet disease-causing variants have been successfully developed for cystic fibrosis (CF) patients. Preclinical...
10.
Hudock K, Clancy J
Expert Opin Emerg Drugs
. 2017 Dec;
22(4):331-346.
PMID: 29264936
Cystic fibrosis (CF) is a genetic disorder that results in a multi-organ disease with progressive respiratory decline that ultimately leads to premature death. CF is caused by mutations in the...